6 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
for1 year (total planned dosing duration is 96 weeks). Interim data readouts are planned to be presented this year at the following conferences: Asian
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
for MASH
Data presented at the Asian Pacific Association for the Study of the Liver (APASL) conference highlighted ALG-055009 Phase 1 data that showed
PRE 14A
6eflm9f
16 Apr 24
Preliminary proxy
5:27pm
- Prev
- 1
- Next